NEOADJUVANT TRIAL DESIGNS


PERJETA, in combination with Herceptin® (trastuzumab) and chemotherapy, has been studied in multiple clinical trials for the neoadjuvant treatment of patients with HER2‑positive breast cancer.1

Learn more about the trial designs, endpoints, and baseline patient characteristics.

NeoSphere trial

TRYPHAENA trial

BERENICE trial

References